Kardium

Vancouver-based Kardium has closed a US$250 million financing round to advance the commercialization of its Globe System for atrial fibrillation treatment. The oversubscribed round included Janus Henderson Investors, Qatar Investment Authority, MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital.

The Globe System features a 122-electrode array enabling rapid pulmonary vein isolation and high-resolution mapping in a single catheter. CEO Kevin Chaplin said the funding will expand manufacturing, support regulatory approvals, and build a commercial team ahead of launch later this year. Clinical data showed 78% freedom from arrhythmia at one year in paroxysmal AF patients.

Want to know more? Check out the source code on Techcouver.com.

Vancouver-based Kardium has raised $143 million in a financing round led by existing investor Fidelity Management & Research Company. The funding will support the completion of the PULSAR clinical study for the Globe Mapping and Ablation System, used to treat atrial fibrillation.

The funds will also help expand Kardium’s manufacturing capabilities and build a clinical support and commercial team for the Globe System’s launch. The Globe System features a catheter with a 122-electrode array and advanced software for rapid pulmonary vein isolation and high-definition mapping.

Want to know more? Check out the source code on Techcouver.